{"cursor":"5110","size":15,"audio":[],"currentlang":"en","article":"'Test data exclusivity' refers to protection of clinical test data required to\nbe submitted to a regulatory agency to prove safety and efficacy of a new drug,\nand prevention of generic drug manufacturers from relying on this data in their\nown applications. Pharmaceutical companies argue that since test data is so\nexpensive to produce, it is an unfair advantage to let other companies rely on\nthat data without cost. Critics charge that it can act as a restriction to\nproducing a generic copy; that although it would not raise prices of drugs, it\nwould prevent prices from falling due to generic competition; and make it more\ncostly for the poor to gain access to life-saving drugs (e.g. anti-HIV & anti-\nmalarial medications.) Developed countries with innovative pharmaceutical\nindustries (including the United States) have sought data exclusivity provisions\nin Free Trade Agreements with their trading partners, e.g. DR-CAFTA which\nincludes such a provision.\n\nAccording to the European Commission:\n:\"\"Data exclusivity\" refers to the period during which the data of the original\n:[[marketing authorisation]] holder relating to (pre-) clinical testing is\n:protected. Accordingly, in relation to marketing authorisation applications\n:submitted after 30 October 2005 for the applications filed in the framework of\n:national procedures or 20 November 2005 for applications filed in the framework\n:of the centralised procedure, 'data exclusivity' refers to the eight-year\n:protection period during which generic applicant may not refer to the\n:information of the original marketing authorisation holder and 'marketing\n:exclusivity' refers to the ten-year period after which generic products can be\n:placed on the market. However, in relation to marketing authorisation\n:applications submitted before the above mentioned dates, the wording 'data\n:exclusivity' refers to the six or ten-year protection period granted to the\n:original MA holder before generic applicants can file their applications for\n:marketing authorisation.\" European Commission, [http://ec.europa.eu/compe-\n:tition/sectors/pharmaceuticals/inquiry/preliminary_report.pdf ''Pharmaceutical\n:Sector Inquiry, Preliminary Report (DG Competition Staff Working Paper)], 28\n:November 2008, page 17 (pdf, 1.95 MB). (See copyright notice in page 1:\n:\"Reproduction of parts of this report that are based on the Commission's own\n:research is authorised, provided that the source is acknowledged. For material\n:quoted in this report that is derived from other sources, permission must be\n:sought directly from the copyright holder.\") \n\nOne critical issue in this regard is the issue of data exclusivity for pioneer\ndrug companies (pharmaceutical R&D organizations). From the standpoint of\neconomics, industries where the R&D process is costly and risky, need longer\nexclusivity periods to realize innovation benefits, compared to those industries\nwhere innovation is easier and less costly.\n\nSome academics allege that pharmaceutical data exclusivity protection unfairly\nrestricts the rapid public dispersal of knowledge that is supposed to be the trade-\noff for a grant of a patent or intellectual monopoly privilege. Faunce TA,\nVines T, Gibbons H. New Forms of Evergreening in Australia: Misleading\nAdvertising, Enantiomers and Data Exclusivity (2008) 16 Journal of Law and\nMedicine 220-232. http://law.anu.edu.au/StaffUploads/236-\nJLM%20evergreeningapotex09.pdf They allege that data exclusivity is really\na form of evergreening pharmaceutical patent protection that may even restrict\nthe capacity of governments to benefit from the granting of a compulsory license\non the patents on a medicine, since the data monopoly will still prevent the\nmarketing of generic products, even though the patent licenses have been granted\nby the government or a court. Faunce TA, Vines T, Gibbons H. New Forms of\nEvergreening in Australia: Misleading Advertising, Enantiomers and Data\nExclusivity (2008) 16 Journal of Law and Medicine 220-232. http://law.anu.edu.au/StaffUploads/236-\nJLM%20evergreeningapotex09.pdf\n\nA separate criticism of data exclusivity concerns medical and research ethics.\nSpecifically, it is considered unethical under the Declaration of Helsinki to\nundertake duplicative clinical trials on human subjects. Similar concerns have\nbeen raised in the context of test data protection for certain agricultural or\ncosmetic products, leading in some countries to proposals for cost sharing\nrather than exclusive rights as the form of test data protection.\n","linknr":95,"url":"Data_exclusivity","recorded":1376421452,"links":["/w/index.php?title=Test_data_exclusivity&action=edit","/w/index.php?title=Test_data_exclusivity&action=edit","//bits.wikimedia.org/favicon/wikipedia.ico","/w/opensearch_desc.php","//en.wikipedia.org/w/api.php?action=rsd","//creativecommons.org/licenses/by-sa/3.0/","/w/index.php?title=Special:RecentChanges&feed=atom","http://en.wikipedia.org/wiki/Test_data_exclusivity","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmw.PopUpMediaTransform%7Cskins.vector&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=ext.visualEditor.viewPageTarget.noscript&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=styles&skin=vector&*","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=startup&only=scripts&skin=vector&*","//bits.wikimedia.org/geoiplookup","//meta.wikimedia.org","/w/index.php?title=Data_exclusivity&redirect=no","#mw-navigation","#p-search","/w/index.php?title=Clinical_test_data&action=edit&redlink=1","/wiki/Regulatory_agency","/wiki/Drug","/wiki/Generic_drug","/wiki/DR-CAFTA","/wiki/European_Commission","/w/index.php?title=Marketing_authorisation&action=edit&redlink=1","#cite_note-1","/wiki/Intellectual_monopoly_privilege","#cite_note-2","/wiki/Evergreening","/wiki/Compulsory_license","#cite_note-3","/w/index.php?title=Test_data_exclusivity&action=edit&section=1","/w/index.php?title=Test_data_exclusivity&veaction=edit&section=1","/w/index.php?title=Test_data_exclusivity&action=edit&section=2","/w/index.php?title=Test_data_exclusivity&veaction=edit&section=2","#cite_ref-1","http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/preliminary_report.pdf","#cite_ref-2","http://law.anu.edu.au/StaffUploads/236-JLM%20evergreeningapotex09.pdf","#cite_ref-3","http://law.anu.edu.au/StaffUploads/236-JLM%20evergreeningapotex09.pdf","//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","http://en.wikipedia.org/w/index.php?title=Test_data_exclusivity&oldid=465544770","/wiki/Help:Category","/wiki/Category:Pharmaceuticals_policy","/w/index.php?title=Special:UserLogin&returnto=Test+data+exclusivity&type=signup","/w/index.php?title=Special:UserLogin&returnto=Test+data+exclusivity","/wiki/Test_data_exclusivity","/wiki/Talk:Test_data_exclusivity","#","/wiki/Test_data_exclusivity","/w/index.php?title=Test_data_exclusivity&action=edit","/w/index.php?title=Test_data_exclusivity&veaction=edit","/w/index.php?title=Test_data_exclusivity&action=history","#","/w/index.php","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","/wiki/Main_Page","/wiki/Main_Page","/wiki/Portal:Contents","/wiki/Portal:Featured_content","/wiki/Portal:Current_events","/wiki/Special:Random","https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en","/wiki/Help:Contents","/wiki/Wikipedia:About","/wiki/Wikipedia:Community_portal","/wiki/Special:RecentChanges","//en.wikipedia.org/wiki/Wikipedia:Contact_us","/wiki/Special:WhatLinksHere/Test_data_exclusivity","/wiki/Special:RecentChangesLinked/Test_data_exclusivity","/wiki/Wikipedia:File_Upload_Wizard","/wiki/Special:SpecialPages","/w/index.php?title=Test_data_exclusivity&oldid=465544770","/w/index.php?title=Test_data_exclusivity&action=info","//www.wikidata.org/wiki/Q7705761","/w/index.php?title=Special:Cite&page=Test_data_exclusivity&id=465544770","/w/index.php?title=Special:Book&bookcmd=book_creator&referer=Test+data+exclusivity","/w/index.php?title=Special:Book&bookcmd=render_article&arttitle=Test+data+exclusivity&oldid=465544770&writer=rl","/w/index.php?title=Test_data_exclusivity&printable=yes","#","//www.wikidata.org/wiki/Q7705761#sitelinks-wikipedia","//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License","//creativecommons.org/licenses/by-sa/3.0/","//wikimediafoundation.org/wiki/Terms_of_Use","//wikimediafoundation.org/wiki/Privacy_policy","//www.wikimediafoundation.org/","//wikimediafoundation.org/wiki/Privacy_policy","/wiki/Wikipedia:About","/wiki/Wikipedia:General_disclaimer","//en.wikipedia.org/wiki/Wikipedia:Contact_us","//en.m.wikipedia.org/wiki/Test_data_exclusivity","//wikimediafoundation.org/","//bits.wikimedia.org/images/wikimedia-button.png","//www.mediawiki.org/","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png","//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&lang=en&modules=site&only=scripts&skin=vector&*"],"instances":[],"pdf":["http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/preliminary_report.pdf","http://law.anu.edu.au/StaffUploads/236-JLM%20evergreeningapotex09.pdf","http://law.anu.edu.au/StaffUploads/236-JLM%20evergreeningapotex09.pdf"],"categories":["Pharmaceuticals policy"],"headings":["Data Exclusivity Period for human use drugs","References"],"image":["//en.wikipedia.org/w/index.php?title=Special:CentralAutoLogin/start&type=1x1&from=enwiki","//bits.wikimedia.org/static-1.22wmf12/skins/vector/images/search-ltr.png?303-4","//bits.wikimedia.org/images/wikimedia-button.png","//bits.wikimedia.org/static-1.22wmf12/skins/common/images/poweredby_mediawiki_88x31.png"],"tags":[],"members":[],"related":["Clinical_test_data","Regulatory_agency","Drug","Generic_drug","DR-CAFTA","European_Commission","Intellectual_monopoly_privilege","Evergreening","Compulsory_license"]}